BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 30984171)

  • 21. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
    Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
    MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
    Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
    Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
    Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
    Front Immunol; 2018; 9():3124. PubMed ID: 30761158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
    Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
    Li G; Zhang L; Chen E; Wang J; Jiang X; Chen JH; Wickman G; Amundson K; Bergqvist S; Zobel J; Buckman D; Baxi SM; Bender SL; Casperson GF; Hu-Lowe DD
    Cancer Res; 2010 Dec; 70(24):10243-54. PubMed ID: 21159645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages.
    Keler T; Wallace PK; Vitale LA; Russoniello C; Sundarapandiyan K; Graziano RF; Deo YM
    J Immunol; 2000 Jun; 164(11):5746-52. PubMed ID: 10820252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.
    Jung ST; Reddy ST; Kang TH; Borrok MJ; Sandlie I; Tucker PW; Georgiou G
    Proc Natl Acad Sci U S A; 2010 Jan; 107(2):604-9. PubMed ID: 20080725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors.
    Noble A; Paudyal B; Schwartz JC; Mwangi W; Munir D; Tchilian E; Hammond JA; Graham SP
    Front Immunol; 2023; 14():1286903. PubMed ID: 38077405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A variant human IgG1-Fc mediates improved ADCC.
    Stewart R; Thom G; Levens M; Güler-Gane G; Holgate R; Rudd PM; Webster C; Jermutus L; Lund J
    Protein Eng Des Sel; 2011 Sep; 24(9):671-8. PubMed ID: 21596686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
    Richards JO; Karki S; Lazar GA; Chen H; Dang W; Desjarlais JR
    Mol Cancer Ther; 2008 Aug; 7(8):2517-27. PubMed ID: 18723496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH.
    Liu Y; Lee AG; Nguyen AW; Maynard JA
    J Biol Chem; 2022 Apr; 298(4):101798. PubMed ID: 35248534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
    Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
    J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of high-affinity anti-CD16A allotype-independent human antibody domains.
    Li W; Yang H; Dimitrov DS
    Exp Mol Pathol; 2016 Oct; 101(2):281-289. PubMed ID: 27712994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.